PIM1 Mouse Monoclonal Antibody
- Known as:
- PIM1 Mouse Monoclonal Antibody
- Catalog number:
- CEL-005292-M18
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- PIM1 Mouse Monoclonal Antibody
Related genes to: PIM1 Mouse Monoclonal Antibody
- Gene:
- LONP1 NIH gene
- Name:
- lon peptidase 1, mitochondrial
- Previous symbol:
- PRSS15
- Synonyms:
- LonHS, hLON, PIM1
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-17
- Date modifiied:
- 2014-11-18
- Gene:
- PIM1 NIH gene
- Name:
- Pim-1 proto-oncogene, serine/threonine kinase
- Previous symbol:
- PIM
- Synonyms:
- -
- Chromosome:
- 6p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: PIM1 Mouse Monoclonal Antibody
Related articles to: PIM1 Mouse Monoclonal Antibody
- Lon protease is a nuclear DNA-encoded mitochondrial enzyme highly conserved throughout evolution, involved in the degradation of damaged and oxidized proteins of the mitochondrial matrix, in the correct folding of proteins imported in mitochondria, and in the maintenance of mitochondrial DNA. Lon expression is induced by various stimuli, including hypoxia and reactive oxygen species, and provides protection against cell stress. Lon down-regulation is associated with ageing and with cell senescence, while up-regulation is observed in tumour cells, and is correlated with a more aggressive phenotype of cancer. Lon up-regulation contributes to metabolic reprogramming observed in cancer, favours the switch from a respiratory to a glycolytic metabolism, helping cancer cell survival in the tumour microenvironment, and contributes to epithelial to mesenchymal transition. Silencing of Lon, or pharmacological inhibition of its activity, causes cell death in various cancer cells. Thus, Lon can be included in the growing class of proteins that are not responsible for oncogenic transformation, but that are essential for survival and proliferation of cancer cells, and that can be considered as a new target for development of anticancer drugs. - Source: PubMed
Publication date: 2015/09/12
Pinti MarcelloGibellini LaraLiu YongzhangXu ShanLu BinCossarizza Andrea